Larry Hsin

Biotech investor, Cell therapy, Gene editing, RNAi and PROTACs

[Larry Hsin @xlp007]

$AFMD These two slides are the fundamental basis and blueprint of AFMD.

[Larry Hsin @xlp007]

@bchydro @reparkable Such a long time. Must be very severe

[Larry Hsin @xlp007]

@dymonsion @alexismesang @dymension Airdrops are a great way to discover promising projects.

[Larry Hsin @xlp007]

@MctisDAOs @MetisDAO @l2beat Excited to be part of this airdrop. Let's make it big!

[Larry Hsin @xlp007]

@MctisDAOs @MetisDAO Joined the airdrop and received my tokens. Let's soar to new heights with this project!

[Larry Hsin @xlp007]

@MctisDAOs @MetisDAO I love how this project rewards its supporters with airdrops.

[Larry Hsin @xlp007]

@kelsieswrites Pray for him

[Larry Hsin @xlp007]

$AFMD There are two points brought to my attention: Peripheral blood NK cells are activated by AFM24 and CD8+ cytotoxic T cells become activated as an indirect effect of AFM24. Next step, we need to see this in tumor tissue.

[Larry Hsin @xlp007]

$FSTX 4 data readouts for all of 4 programs in 2022. Multiple partnerships with big pharms. Focus on FS118: Phase 2 refractory head and neck cancer with data expected in mid-2022, especially after BMY's Opdualag™ (nivolumab and relatlimab) got approved last month.

[Larry Hsin @xlp007]

$AFMD $XNCR $APVO $IMGN CD123 is a challenging target. The bispecific antibody, monoclonal antibodies, fusion proteins, ADCs, CAR-T all experienced frustration. I think AFM28 to target CD123 is reasonable. Let's see

[Larry Hsin @xlp007]

$AFMD I think more likely AFM32 is for HER2

[Larry Hsin @xlp007]

$AFMD $BCYC Is anyone familiar with Ridgeback Capital Investments? It only holds 3 stocks: BCYC, AFMD and FSTX. BCYC accounts for around 58% of the portfolio and AFMD is 35%. Is it that possible Ridgeback was involved in the recent market performance of BCYC and AFMD?

[Larry Hsin @xlp007]

$AFMD As for AFMD24, I do start to have positive expectations. There are 29 heavily pretreated nonselective patients with a variety of tumors(RAS mut), only 5 on 480mg(RP2D) and 6 on 320mg. Three patients had stable disease for ≥3 months. The rest of 2022 is catalysts flourish.